Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Open, prospective, multicenter phase IV study to evaluate the impact of pharmacogenetic markers on the efficacy and side effect rate in postmenopausal, steroid hormone receptor positive breast cancer patients treated with letrozole.

Next Previous
Trial Profile

Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Open, prospective, multicenter phase IV study to evaluate the impact of pharmacogenetic markers on the efficacy and side effect rate in postmenopausal, steroid hormone receptor positive breast cancer patients treated with letrozole.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer; HER2 positive breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms PreFace

Most Recent Events

  • 24 Jul 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01908556).
  • 24 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 08 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top